We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Immuron Ltd | NASDAQ:IMRN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.32 | 2.18 | 2.44 | 2.35 | 2.265 | 2.27 | 4,930 | 22:16:11 |
From Nov 2023 to May 2024
CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones.
Following the presentation, attendees will have the opportunity to ask questions directly to Mr Lydeamore during a moderated Q & A session.
This webinar can be viewed live via zoom & you register via the link below.
Zoom: https://us02web.zoom.us/webinar/register/WN_73dRq8CsQK6Ahor0F8UzgA#/registration
Authorised for release by the Board of Immuron Limited.
| COMPANY CONTACT:Steven LydeamoreChief Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
1 Year Immuron Chart |
1 Month Immuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
